Galactooligosaccharide supplementation provides protection against citrobacter rodentium-induced colitis without limiting pathogen burden

Hatem Kittana, Maria I. Quintero-Villegas, Laure B. Bindels, João Carlos Gomes-Neto, Robert J. Schmaltz, Rafael R. Segura Munoz, Liz A. Cody, Rodney A. Moxley, Jesse Hostetter, Robert W. Hutkins, Amanda E. Ramer-Tait

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Many enteric pathogens, including Salmonella and enteropathogenic and enterohemorrhagic Escherichia coli, express adhesins that recognize and bind to carbohydrate moieties expressed on epithelial cells. An attractive strategy for inhibiting bacterial adherence employs molecules that mimic these epithelial binding sites. Prebiotic oligosaccharides are nondigestible, fermentable fibres capable of modulating the gut microbiota. Moreover, they may act as molecular decoys that competitively inhibit adherence of pathogens to host cells. In particular, galactooligosaccharides (GOS) and other prebiotic fibres have been shown to inhibit pathogen adherence to epithelial cells in vitro. In the present study, we determined the ability of prophylactic GOS administration to reduce enteric pathogen adherence both in vitro and in vivo as well as protect against intestinal inflammation. GOS supplementation significantly reduced the adherence of the epithelial-adherent murine bacterial pathogen Citrobacter rodentium in a dose-dependent manner to the surface of epithelial cells in vitro. A 1- to 2-log reduction in bacterial adherence was observed at the lowest and highest doses tested, respectively. However, mouse studies revealed that treatment with GOS neither reduced the adherence of C. rodentium to the distal colon nor decreased its dissemination to systemic organs. Despite the absence of adherence inhibition, colonic disease scores for GOS-treated, C. rodentium-infected mice were significantly lower than those of untreated C. rodentium-infected animals (P=0.028). Together, these data suggest that GOS has a direct protective effect in ameliorating disease severity following C. rodentium infection through an anti-adherence-independent mechanism.

Original languageEnglish (US)
Article number000593
Pages (from-to)154-162
Number of pages9
JournalMicrobiology (United Kingdom)
Volume164
Issue number2
DOIs
StatePublished - Feb 2018

Fingerprint

Citrobacter rodentium
Colitis
Prebiotics
Epithelial Cells
Escherichia coli Adhesins
Colonic Diseases
Enterohemorrhagic Escherichia coli
Enteropathogenic Escherichia coli
Oligosaccharides
Salmonella
Colon
Binding Sites
Carbohydrates
Inflammation
Infection
In Vitro Techniques

Keywords

  • Anti-adherence
  • Citrobacter rodentium
  • Conventionally-raised mice
  • Gastrointestinal inflammation
  • Prebiotics

ASJC Scopus subject areas

  • Microbiology

Cite this

Kittana, H., Quintero-Villegas, M. I., Bindels, L. B., Gomes-Neto, J. C., Schmaltz, R. J., Segura Munoz, R. R., ... Ramer-Tait, A. E. (2018). Galactooligosaccharide supplementation provides protection against citrobacter rodentium-induced colitis without limiting pathogen burden. Microbiology (United Kingdom), 164(2), 154-162. [000593]. https://doi.org/10.1099/mic.0.000593

Galactooligosaccharide supplementation provides protection against citrobacter rodentium-induced colitis without limiting pathogen burden. / Kittana, Hatem; Quintero-Villegas, Maria I.; Bindels, Laure B.; Gomes-Neto, João Carlos; Schmaltz, Robert J.; Segura Munoz, Rafael R.; Cody, Liz A.; Moxley, Rodney A.; Hostetter, Jesse; Hutkins, Robert W.; Ramer-Tait, Amanda E.

In: Microbiology (United Kingdom), Vol. 164, No. 2, 000593, 02.2018, p. 154-162.

Research output: Contribution to journalArticle

Kittana, H, Quintero-Villegas, MI, Bindels, LB, Gomes-Neto, JC, Schmaltz, RJ, Segura Munoz, RR, Cody, LA, Moxley, RA, Hostetter, J, Hutkins, RW & Ramer-Tait, AE 2018, 'Galactooligosaccharide supplementation provides protection against citrobacter rodentium-induced colitis without limiting pathogen burden', Microbiology (United Kingdom), vol. 164, no. 2, 000593, pp. 154-162. https://doi.org/10.1099/mic.0.000593
Kittana, Hatem ; Quintero-Villegas, Maria I. ; Bindels, Laure B. ; Gomes-Neto, João Carlos ; Schmaltz, Robert J. ; Segura Munoz, Rafael R. ; Cody, Liz A. ; Moxley, Rodney A. ; Hostetter, Jesse ; Hutkins, Robert W. ; Ramer-Tait, Amanda E. / Galactooligosaccharide supplementation provides protection against citrobacter rodentium-induced colitis without limiting pathogen burden. In: Microbiology (United Kingdom). 2018 ; Vol. 164, No. 2. pp. 154-162.
@article{8b14e5f3c03d41308be056f0af754581,
title = "Galactooligosaccharide supplementation provides protection against citrobacter rodentium-induced colitis without limiting pathogen burden",
abstract = "Many enteric pathogens, including Salmonella and enteropathogenic and enterohemorrhagic Escherichia coli, express adhesins that recognize and bind to carbohydrate moieties expressed on epithelial cells. An attractive strategy for inhibiting bacterial adherence employs molecules that mimic these epithelial binding sites. Prebiotic oligosaccharides are nondigestible, fermentable fibres capable of modulating the gut microbiota. Moreover, they may act as molecular decoys that competitively inhibit adherence of pathogens to host cells. In particular, galactooligosaccharides (GOS) and other prebiotic fibres have been shown to inhibit pathogen adherence to epithelial cells in vitro. In the present study, we determined the ability of prophylactic GOS administration to reduce enteric pathogen adherence both in vitro and in vivo as well as protect against intestinal inflammation. GOS supplementation significantly reduced the adherence of the epithelial-adherent murine bacterial pathogen Citrobacter rodentium in a dose-dependent manner to the surface of epithelial cells in vitro. A 1- to 2-log reduction in bacterial adherence was observed at the lowest and highest doses tested, respectively. However, mouse studies revealed that treatment with GOS neither reduced the adherence of C. rodentium to the distal colon nor decreased its dissemination to systemic organs. Despite the absence of adherence inhibition, colonic disease scores for GOS-treated, C. rodentium-infected mice were significantly lower than those of untreated C. rodentium-infected animals (P=0.028). Together, these data suggest that GOS has a direct protective effect in ameliorating disease severity following C. rodentium infection through an anti-adherence-independent mechanism.",
keywords = "Anti-adherence, Citrobacter rodentium, Conventionally-raised mice, Gastrointestinal inflammation, Prebiotics",
author = "Hatem Kittana and Quintero-Villegas, {Maria I.} and Bindels, {Laure B.} and Gomes-Neto, {Jo{\~a}o Carlos} and Schmaltz, {Robert J.} and {Segura Munoz}, {Rafael R.} and Cody, {Liz A.} and Moxley, {Rodney A.} and Jesse Hostetter and Hutkins, {Robert W.} and Ramer-Tait, {Amanda E.}",
year = "2018",
month = "2",
doi = "10.1099/mic.0.000593",
language = "English (US)",
volume = "164",
pages = "154--162",
journal = "Microbiology",
issn = "1350-0872",
publisher = "Maik Nauka-Interperiodica Publishing",
number = "2",

}

TY - JOUR

T1 - Galactooligosaccharide supplementation provides protection against citrobacter rodentium-induced colitis without limiting pathogen burden

AU - Kittana, Hatem

AU - Quintero-Villegas, Maria I.

AU - Bindels, Laure B.

AU - Gomes-Neto, João Carlos

AU - Schmaltz, Robert J.

AU - Segura Munoz, Rafael R.

AU - Cody, Liz A.

AU - Moxley, Rodney A.

AU - Hostetter, Jesse

AU - Hutkins, Robert W.

AU - Ramer-Tait, Amanda E.

PY - 2018/2

Y1 - 2018/2

N2 - Many enteric pathogens, including Salmonella and enteropathogenic and enterohemorrhagic Escherichia coli, express adhesins that recognize and bind to carbohydrate moieties expressed on epithelial cells. An attractive strategy for inhibiting bacterial adherence employs molecules that mimic these epithelial binding sites. Prebiotic oligosaccharides are nondigestible, fermentable fibres capable of modulating the gut microbiota. Moreover, they may act as molecular decoys that competitively inhibit adherence of pathogens to host cells. In particular, galactooligosaccharides (GOS) and other prebiotic fibres have been shown to inhibit pathogen adherence to epithelial cells in vitro. In the present study, we determined the ability of prophylactic GOS administration to reduce enteric pathogen adherence both in vitro and in vivo as well as protect against intestinal inflammation. GOS supplementation significantly reduced the adherence of the epithelial-adherent murine bacterial pathogen Citrobacter rodentium in a dose-dependent manner to the surface of epithelial cells in vitro. A 1- to 2-log reduction in bacterial adherence was observed at the lowest and highest doses tested, respectively. However, mouse studies revealed that treatment with GOS neither reduced the adherence of C. rodentium to the distal colon nor decreased its dissemination to systemic organs. Despite the absence of adherence inhibition, colonic disease scores for GOS-treated, C. rodentium-infected mice were significantly lower than those of untreated C. rodentium-infected animals (P=0.028). Together, these data suggest that GOS has a direct protective effect in ameliorating disease severity following C. rodentium infection through an anti-adherence-independent mechanism.

AB - Many enteric pathogens, including Salmonella and enteropathogenic and enterohemorrhagic Escherichia coli, express adhesins that recognize and bind to carbohydrate moieties expressed on epithelial cells. An attractive strategy for inhibiting bacterial adherence employs molecules that mimic these epithelial binding sites. Prebiotic oligosaccharides are nondigestible, fermentable fibres capable of modulating the gut microbiota. Moreover, they may act as molecular decoys that competitively inhibit adherence of pathogens to host cells. In particular, galactooligosaccharides (GOS) and other prebiotic fibres have been shown to inhibit pathogen adherence to epithelial cells in vitro. In the present study, we determined the ability of prophylactic GOS administration to reduce enteric pathogen adherence both in vitro and in vivo as well as protect against intestinal inflammation. GOS supplementation significantly reduced the adherence of the epithelial-adherent murine bacterial pathogen Citrobacter rodentium in a dose-dependent manner to the surface of epithelial cells in vitro. A 1- to 2-log reduction in bacterial adherence was observed at the lowest and highest doses tested, respectively. However, mouse studies revealed that treatment with GOS neither reduced the adherence of C. rodentium to the distal colon nor decreased its dissemination to systemic organs. Despite the absence of adherence inhibition, colonic disease scores for GOS-treated, C. rodentium-infected mice were significantly lower than those of untreated C. rodentium-infected animals (P=0.028). Together, these data suggest that GOS has a direct protective effect in ameliorating disease severity following C. rodentium infection through an anti-adherence-independent mechanism.

KW - Anti-adherence

KW - Citrobacter rodentium

KW - Conventionally-raised mice

KW - Gastrointestinal inflammation

KW - Prebiotics

UR - http://www.scopus.com/inward/record.url?scp=85041857980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041857980&partnerID=8YFLogxK

U2 - 10.1099/mic.0.000593

DO - 10.1099/mic.0.000593

M3 - Article

C2 - 29256851

AN - SCOPUS:85041857980

VL - 164

SP - 154

EP - 162

JO - Microbiology

JF - Microbiology

SN - 1350-0872

IS - 2

M1 - 000593

ER -